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DOI 10.1186/s12885-017-3861-9RESEARCH ARTICLE Open AccessEvaluation of plasma brain-derived
neurotrophic factor levels and
self-perceived cognitive impairment
post-chemotherapy: a longitudinal study
Terence Ng1,2†, Ying Yun Lee1†, Jung-woo Chae1,2, Angie Hui Ling Yeo1, Maung Shwe1, Yan Xiang Gan2,
Raymond C. H. Ng3,4, Pat Pak Yan Chu5, Chiea Chuen Khor6, Han Kiat Ho1 and Alexandre Chan1,2,3*Abstract
Background: Preliminary evidence suggests that changes in plasma brain-derived neurotrophic factor (BDNF) levels
may contribute to the occurrence of chemotherapy-associated cognitive impairment (CACI), and a previous study
suggested that carriers of the BDNF Met homozygous genotype are protected from CACI.
Methods: This multicenter, prospective cohort study involved chemotherapy-receiving early-stage breast cancer
(ESBC) patients. Self-perceived cognitive function was longitudinally assessed using the validated FACT-Cog (ver. 3)
across three time points: Prior to chemotherapy (T1), during chemotherapy (T2), and at the end of chemotherapy
(T3). Plasma BDNF levels were quantified using enzyme-linked immunosorbent assay. Genotyping was performed
using Sanger Sequencing.
Results: A total of 51 chemotherapy-receiving ESBC patients (mean age: 52.6 ± 9.5 years) were recruited, and 11
patients (21.6%) reported subjective cognitive impairment post-chemotherapy. Overall, there was a reduction in
median plasma BDNF levels over time (T1: 5423.0 pg/ml; T2: 5313.6 pg/ml; T3: 4050.3 pg/ml; p < 0.01). After
adjusting for confounding factors, longitudinal analysis revealed that BDNF levels were associated with self-reported
concentration deficit (p = 0.032). Carriers of Val/Val (p = 0.011) and Val/Met (p = 0.003) BDNF genotypes demonstrated a
significant reduction in plasma BDNF levels over time; however, plasma BDNF levels were similar across all time points
among Met homozygous carriers (p = 0.107).
Conclusion: There was a statistically significant change in BDNF levels post-chemotherapy in ESBC patients, and
plasma BDNF levels were associated with self-perceived concentration deficit in patients receiving chemotherapy.
Keywords: BDNF, Breast cancer, Cognition, Genetics, rs6265Background
Chemotherapy-associated cognitive impairment (CACI)
among breast cancer survivors has been widely reported
[1]. Often termed as “chemobrain,” cognitive changes are
subtle, yet notable. Memory, attention, and executive* Correspondence: phaac@nus.edu.sg
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induced changes, and these changes may adversely affect
a patient’s daily functioning and quality of life.
While numerous mechanisms to explain chemobrain
have been postulated, including direct chemotherapy-
induced toxicities, immunologic alterations, and neural
repair insufficiencies, little is definitively known about
its actual causes. Of the proposed mechanisms, it has
been suggested that the brain-derived neurotrophic
factor (BDNF) may be implicated in CACI. BDNF is a type
of neurotrophin extensively distributed in the central ner-
vous system, particularly in the prefrontal cortex andle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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related kinase B receptors [5], BDNF plays an essential
role in regulating synaptic plasticity, neuronal growth, and
survival [3, 4, 6]. In particular, it has been noted for its
involvement in neurotransmitter release and long-term
potentiation (LTP) [3, 4]. Long-term potentiation is
important to memory and learning, and the inhibition of
LTP may result in hippocampal-dependent memory
impairment [7].
Numerous studies have reported the possible role of
BDNF in the pathogenesis of various cognitive disorders,
such as Alzheimer’s disease [3, 4, 6, 8, 9]. Low serum
BDNF levels have been correlated with Alzheimer’s dis-
ease and mild cognitive impairment, and high serum
BDNF levels have been associated with better cognition
in healthy older adults. Studies have also suggested that
plasma BDNF reflects cortical BDNF signaling during
learning in healthy adults [10]. Consistent with the in-
creasing evidence for BDNF’s role in cognition, studies
have also noted the contribution of BDNF Val66Met
polymorphism (rs6265) in cognitive function and various
neuropsychiatric disorders [11]. Our research group re-
cently revealed that rs6265 confers a protective effect
against CACI in the early-stage breast cancer (ESBC)
population [12]. However, the trajectory of plasma
BDNF during chemotherapy and its relation with rs6265
remain unknown.
Given the possible implication of BDNF in cognition,
it is worthwhile exploring the possible association of
peripheral BDNF levels and cognitive function in the
chemotherapy-receiving cancer population. Hence, this
pilot study was designed to investigate the changes of
plasma BDNF levels and self-perceived cognitive impair-
ment in ESBC patients receiving chemotherapy. A second-
ary objective of this study was to investigate the differences
in plasma BDNF levels between the rs6265 genotypes.
Methods
Study design and participants
This was a prospective cohort study conducted at the
National Cancer Centre Singapore and KK Women’s and
Children’s Hospital between November 2014 to December
2015. This study was conducted in accordance to the
Declaration of Helsinki and approved by SingHealth
Institutional Review Board (CIRB 2014/754/B). Patients were
given informed consent before recruitment. The inclusion
criteria of this study were: (1) age ≥ 21 years, (2) understood
English or Mandarin, (3) diagnosed with ESBC (stage I-IIIa),
(4) scheduled for anthracycline- or taxane-based chemother-
apy, and (5) had no prior history of chemotherapy and/or
radiotherapy. Exclusion criteria include (1) incapable of
giving informed consent, (2) symptomatically ill, (3) presence
of neuropsychiatric disorders, and (4) presence of neurologic
or immune-related conditions.Procedures
At the point of recruitment, patients’ demographics and
medical information were obtained via electronic med-
ical records and patient interviews. Patients’ self-
perceived cognitive function and behavioral symptoms
were assessed using subjective assessment tools at three
time points in approximately 6-week intervals: baseline
(T1), during (T2) and at the end of chemotherapy (T3).
The assessments were conducted either in English or
Chinese by trained personnel. Each session was approxi-
mately 45 min. At each time point, 10 mL of whole
blood was collected in a heparinized-tube and immedi-
ately centrifuged at 2500 rpm for 10 min. The plasma
and buffy coat were stored at −80 °C until analysis.
Assessment of self-perceived cognitive impairment
The Functional Assessment of Cancer Therapy-
Cognitive Function (FACT-Cog) version is a 37-item
questionnaire which evaluates patients’ self-perceived
cognitive decline within the past 7 days, and this tool
has been validated for usage in our population [13]. Six
domains of cognition (mental acuity, attention and con-
centration, memory, verbal fluency, functional interfer-
ence and multitasking ability) are evaluated on a scale of
0 (“Never” or “Not at all”) to 4 (“Several times a day” or
“Very much”). Reverse scores from individual items are
tallied to obtain the global FACT-Cog score. A higher
score denotes better self-perceived cognitive function.
The patients were classified as having self-perceived cogni-
tive impairment if there was a reduction of at least 10.6
points in the global FACT-Cog score at T2 or T3 relative
to the baseline value. For each cognitive subdomain, a 15%
decrease score reduction at T2 or T3 relative to the base-
line value is considered as impairment. This classification
has been utilized in other studies that evaluated self-
perceived cognitive impairment in cancer patients [12, 14].
Assessment of cancer-related fatigue
Cancer-related fatigue was assessed using the Brief
Fatigue Inventory (BFI) [15]. The BFI measures the severity
of fatigue (a known confounder of cognition) at the point
of assessment and in the past 24 h, rated in a scale of 0
(“no fatigue”) to 10 (“fatigue as bad as you can imagine”).
BFI assesses whether fatigue interfere on daily activities in
the past 24 h, on a scale of 0 (“does not interfere”) to 10
(“completely interferes”). Six aspects of interference were
assessed: general activity, mood, walking ability, normal
work, relations with other people and enjoyment of life.
Assessment of anxiety
Anxiety was assessed using the Beck Anxiety Inventory
(BAI), and this tool has been validated for usage in our
population [16]. The BAI measures the severity of anxiety,
a known confounder of cognition, in the past month
Ng et al. BMC Cancer  (2017) 17:867 Page 3 of 9based on 21 items listing common anxiety symptoms, on
a scale of 0 (“not at all”) to 3 (“severe”). Scores from indi-
vidual items were tallied to obtain a global score. A higher
score denotes greater anxiety.
Assessment of depression
Depression was assessed using the Beck Depression
Inventory (BDI) [17]. The BDI evaluates 21 symptoms of
depression (14 cognitive-affective symptoms, 7 somatic
symptoms) on a four-point intensity scale. Scores were
tallied to a total score. A higher score reflects greater se-
verity of depression.
Plasma BDNF quantification
Plasma BDNF levels were analyzed in duplicate using a
commercial enzyme-linked immunosorbent assay (ELISA)
kit (Biosensis® BEK-2211-2P, Australia) according to the
manufacturer’s instructions. The kit detects 100% of the
mature BDNF, with less than 7% cross-reactivity with the
pro-form of BDNF. Brain-derived neurotrophic factor
standards (7.8–500.0 pg/mL) were prepared via serial dilu-
tions, and the plasma samples underwent dilution by a
factor of 50. Brain-derived neurotrophic factor was quan-
tified at 450 nm using a plate reader. The standard curve
was constructed using a four-parameter logistic model
using ElisaAnalysis.com (Leading Technology Group,
Australia) software. An intra-assay coefficient of variance
(CV) of less than 10% was considered to be acceptable.
Genotyping
Genomic DNA from the buffy coat was isolated using a
QIAamp DNA Blood Mini Kit (Qiagen, Germany). The
region containing the BDNF rs6265 polymorphism was
amplified by polymerase chain reaction (PCR) using spe-
cific and optimized primers. The primers involved were:
5′-GGACTCTGGAGAGCGTGAA-3′ (forward) and
5′-CGTGTACAAGTCTGCGTCCT-3 (reverse). Genotyping
of the PCR products was performed by automated Sanger
sequencing using a 3730xl DNA Analyzer (Applied
Biosystems, United States). Samples were identified only by
codes, and genotyping was blindly performed by AITbiotech
without knowledge of the clinical outcomes.
Statistical analysis
All of the statistical analyses were performed using Stata
Version 14 (StataCorp, 2015). Descriptive statistics were
utilized to summarize the demographic and clinical
characteristics of the patients. The Friedman test was
utilized to evaluate changes in the plasma BDNF levels
over time, and the post-hoc Wilcoxon signed-rank test
was used for pair-wise comparisons between individual time
points. Deviation of the genotypes from Hardy-Weinberg
equilibrium was calculated using the chi-squared test with
one degree of freedom.To investigate the association between plasma BDNF
levels and self-perceived cognitive function (overall and
each of the six domains) over time, we created a
generalized estimating equations (GEE) model.
Selection of the appropriate correlation structures in
the GEE model was conducted using the quasi-
likelihood under the independence model criterion,
the structure exhibiting the smallest criterion was
considered as the most desirable. Documented
confounders of BDNF levels and self-perceived CACI
(fatigue, anxiety, depression, age, body mass index
(BMI) and BDNF genotypes) were included in the
statistical model [12, 18].
Subgroup analyses were performed to determine the
change in plasma BDNF levels after classifying for self-
perceived cognitive impairment and the BDNF rs6265
genotypes. The Kruskal-Wallis test and Mann-Whitney
U test were used to analyze cross-sectional differences in
plasma BDNF levels between the genotypes and to
analyze differences in plasma BDNF levels between cog-
nitively impaired and non-impaired population. All of
the statistical tests were two-sided, and p < 0.05 was con-
sidered to correspond to statistical significance.Results
Demographics and clinical information
The analysis included 51 ESBC patients with a mean age
of 52.6 ± 9.5 years (Table 1). The patients were predomin-
antly Chinese (78.4%), and 44 patients (86.2%) had com-
pleted at least secondary school. Thirty-two patients
(62.8%) were diagnosed with stage II breast cancer. All of
the patients were ambulatory without activity restrictions.
Twenty-nine patients (56.9%) received anthracycline-
based chemotherapy, and 22 patients (43.1%) received
taxane-based chemotherapy. Using the Minimal Clinical
Important Difference (MCID) of the FACT-Cog, 11 pa-
tients (21.6%) were classified as manifesting self-perceived
cognitive impairment.
Analysis of the behavioral symptoms revealed a stat-
istical significant increase in median fatigue levels
(0.67 at T1 vs. 1.67 at T3, p < 0.001). Median anxiety
levels, as measured by BAI, increased from 0 at T1 to
6 at T3 (p = 0.040), while depression severity, as mea-
sured by BDI, increased from a median score of 3 at
T1 to 6 at T3 (p < 0.001).Genotypes and allele frequencies
Fifty patients were successfully genotyped for the BDNF
rs6265 polymorphism. The genotype frequency did not
deviate from the Hardy-Weinberg Equilibrium (χ2 = 0.07,
p > 0.05). The Val (52.0%) and Met (48.0%) allele fre-
quency was approximately equivalent. (Table 2).
Table 1 Demographics and clinical information of patients
(n = 51)
Characteristics n (%)
Age (years, mean ± SD) 52.6 ± 9.5
Race Chinese 40 (78.4)
Malay 4 (7.8)
Indian 6 (11.8)
Other 1 (2.0)
Marital status Single 8 (15.7)
Married 40 (78.4)
Divorced 3 (5.9)
Education level None 1 (2.0)
Primary school 6 (11.8)
Secondary school 22 (43.1)
Pre-university 7 (13.7)
Graduate/postgraduate 15 (29.4)
Occupation Currently working 36 (70.6)
Currently not working 13 (25.4)
Retired 1 (2.0)
Long-term medical leave 1 (2.0)
Cancer diagnosis Stage I 7 (13.7)
Stage II 32 (62.8)
Stage III 12 (23.5)
ECOG Performance status 0 51 (100.0)
Menopausal status Pre-menopausal 20 (39.2)
Post-menopausal 31 (60.8)
Chemotherapy regimen Anthracycline-based 29 (56.9)
Taxane-based 22 (43.1)
Behavioral symptoms, median (IQR)
Baseline fatigue (BFI total score, out of 10) 0.7 (0.1,1.8)
Baseline anxiety (BAI total score, out of 63) 0.0 (0.0,0.0)
Baseline depression (BDI total score, out of 63) 3.0 (1.0,8.0)
Abbreviations: SD standard deviation, IQR interquartile range, ECOG Eastern
Cooperative Oncology Group, BFI Brief Fatigue Inventory, BAI Beck Anxiety
Inventory, BDI Beck Depression Inventory
Table 2 Genotype and allele frequencies of the BDNF Val66Met
polymorphism (N = 50)a
Population, n (%) Pooled
Asians,
n (%)
Chinese Malay Indiana Othersb
(n=40) (n=4) (n=5) (n=1) (n=50)
Genotype frequency
GG (Val/Val) 11 (27.5) 1 (25.0) 2 (40.0) 0 (0.0) 14 (28.0)
GA (Val/Met) 18 (45.0) 3 (75.0) 2 (40.0) 1 (100.0) 24 (48.0)
AA (Met/Met) 11 (27.5) 0 (0.0) 1 (20.0) 0 (0.0) 12 (24.0)
Allele frequency
G (Val) allele 40 (50.0) 5 (62.5) 6 (60.0) 1 (50.0) 52 (52.0)
A (Met) allele 40 (50.0) 3 (37.5) 4 (40.0) 1 (50.0) 48 (48.0)
aGenotype data for one patient is not available
bOthers include 1 Filipino
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All of the plasma BDNF levels fell within the BDNF
standard curve (7.8–500.0 pg/mL) after dilution. The
range of BDNF levels detected with ELISA, after correct-
ing for the dilution factor, was 538.6–23,218.7 pg/mL.
The mean intra-assay CV obtained was 4.9%. There was
a statistically significant difference in BDNF levels across
the three time points (T1: 5423.0 vs. T2: 5313.6 vs. T3:
4050.3 pg/mL; p < 0.001), with a decreasing trend over
time (Fig. 1a).
Among individuals who were cognitively impaired (n=11),
BDNF levels were statistically different over time (T1: 5423.0
vs. T2: 5823.2 vs. T3: 3095.7 pg/mL; p= 0.029) (Fig. 1b). A
post-hoc comparison of BDNF levels at T3 versus T1 wasstatistically significant (p=0.016). Similarly, non-impaired indi-
viduals (n=40) experienced a significant reduction in BDNF
levels across the three-time points (p < 0.001).
A comparison of plasma BDNF levels at baseline did
not reveal statistically significant difference between self-
perceived cognitively impaired (5423.0 pg/mL) and non-
impaired individuals (5430.0 pg/mL) (p = 0.664). Similarly,
plasma BDNF levels were similar between the impaired
and non-impaired populations during chemotherapy
(5823.2 pg/mL vs. 5313.6 pg/mL; p = 0.309) and after
chemotherapy (3095.7 vs. 4069.5 pg/mL; p = 0.336).Associations between plasma BDNF levels and self-
perceived CACI
After accounting for known confounders of self-
reported cognitive impairment, the GEE model re-
vealed that BDNF levels were found to be associated
with self-perceived concentration deficit. (Table 3).
BAI was associated with the proportion of overall
self-perceived cognitively impaired individuals over
time (p < 0.001). BAI was also associated with self-
perceived mental acuity deficit (p = 0.001), self-
perceived concentration deficit (p = 0.047), self-
perceived memory deficit (p = 0.007), self-perceived ver-
bal fluency interference (p = 0.001), self-perceived func-
tional interference (p = 0.006) and self-perceived multi-
tasking ability interference (p = 0.001), while BFI was asso-
ciated with self-perceived concentration deficit (p < 0.001),
self-perceived memory deficit (p= 0.009) and self-perceived
functional interference (p= 0.040).
The BDNF Met risk allele was found to be associ-
ated with both overall self-perceived cognitive impair-
ment (p = 0.041) and self-perceived concentration
deficit (p = 0.043). There were no statistically signifi-
cant associations between self-perceived cognitive dis-
turbances with age and BMI.
Fig. 1 Trajectory of plasma BDNF levels over time (n = 51). a Classified based on the entire patient pool; b classified based on overall cognition status;
c classified based on BDNF rs6265 genotypes; d the Friedman test was used to evaluate changes in the plasma BDNF levels over time, e Post-hoc
analysis was conducted using the Wilcoxon signed rank test for pair-wise comparisons. *P values are significant if they are less than 0.0167
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Ng et al. BMC Cancer  (2017) 17:867 Page 7 of 9Change of plasma BDNF levels in relation to BDNF
Val66Met polymorphism classification
There was a statistically significant change in plasma
BDNF levels over time among the Val/Val (p = 0.011)
and Val/Met genotype (p = 0.003); however, the change
was not statistically significant among carriers of the
Met/Met genotype (p = 0.107) (Fig. 1c).
Discussion
Given the role of BDNF in mediating synaptic plasticity
and neuronal growth in the hippocampus, studies have
suggested BDNF’s involvement in cognitive function,
particularly in learning and memory [3, 4, 6, 7]. This
study sought to investigate the changes of plasma BDNF
levels and self-perceived cognitive impairment in ESBC
patients receiving chemotherapy. We have observed a
statistically significant change in plasma BDNF levels
over time post-chemotherapy, and such observation was
relevant in both self-perceived cognitive impaired and
non-impaired subgroups. To further elucidate the
relationship between BDNF levels and self-perceived
cognitive impairment, after adjusting for known con-
founders (including BFI, BAI, BDI, age, BMI and BDNF
genotypes) of self-perceived cognitive impairment, our
longitudinal model revealed that BDNF levels were asso-
ciated with self-perceived concentration deficit. However,
changes in BDNF levels were not observed among those
who were Met homozygous carriers of the BDNF genotype.
Although we have observed an association between
BDNF levels and self-perceived concentration deficit,Fig. 2 Schematic illustration of the biological processing of BDNF. Abbr
brain-derived neurotrophic factor; tPA, tissue plasminogen activator; MM
P75NTR, p75 neurotrophin receptorthe findings are not consistent with other published
studies. Such inconsistencies could be attributed to
differences in the study designs, disease populations,
and cognitive assessment tools. Previous studies were
mainly cross-sectional in nature, and they were con-
ducted in non-cancerous populations. A number of
longitudinal studies did not establish any associations
between serum BDNF levels and cognitive decline in
healthy older adults [19, 20]. However, one study re-
vealed that BDNF levels in the cerebrospinal fluid
(CSF) were significantly associated with greater de-
cline in cognitive function, specifically within the
memory domain in healthy older adults [21]. This
finding suggests that plasma BDNF levels may not be
fully representative of the CSF BDNF levels in the
brain. Although BDNF is able to cross the blood-
brain barrier [22], the degree to which plasma BDNF
levels can represent CSF BDNF levels remains unclear
[23, 24]. Further investigations have to be conducted
to draw a conclusion on the use of plasma BDNF
levels as a surrogate marker for CSF BDNF levels.
Emerging studies have highlighted the contrasting
roles of BDNF isoforms in cognition [25–28]. Biologic-
ally, BDNF is synthesized as a precursor known as
proBDNF prior to cleavage into the mature BDNF
(mBDNF) via furin intracellularly or matrix metallopro-
teinases (MMP) and plasmin extracellularly [26, 27, 29]
(Fig. 2). ProBDNF is necessary for promoting the folding
of the mature domain and for sorting BDNF into
secretory vesicles. While mBDNF regulates neuronaleviation: BDNF, brain-derived neurotrophic factor; mBDNF, mature
P, matrix metalloproteinases; TrkB, tropomyosin-related kinase B;
Ng et al. BMC Cancer  (2017) 17:867 Page 8 of 9growth and survival, proBDNF preferentially binds to
p75 neurotrophin receptor (p75NTR) to activate neur-
onal apoptotic pathways [27, 30]. In a sample of autistic
patients, it was suggested that an imbalance in BDNF
isoforms may have been a possible mechanism leading
to autism [25]. High plasma BDNF levels may not indi-
cate better cognition if proBDNF predominates over
BDNF, which results in greater neuronal apoptosis.
Another study revealed that the direction of BDNF regu-
lation could be affected by mechanisms controlling the
cleavage of proBDNF [31]. High-frequency stimulation
was found to promote the release of proBDNF and tissue
plasminogen activator; low-frequency stimulation only
resulted in proBDNF release. However, this study did
not evaluate the expressions levels of proBDNF. Future
studies should evaluate the ratio between mBDNF and
proBDNF in the context of CACI.
In this study, the Met risk allele is associated with
both overall self-perceived cognitive impairment and
self-perceived concentration deficit. This is in agree-
ment with the literature that the BDNF Val66Met
polymorphism (rs6265) may contribute to varying
cognitive function. One study has suggested that the
Met allele confers a protective effect against CACI in
patients receiving chemotherapy, specifically in the
areas of verbal fluency and multitasking ability [12].
The BDNF Val66Met polymorphism involves a
non-synonymous single nucleotide polymorphism
(SNP) that results in the substitution of Valine to
Methionine at codon66 at the proBDNF region. As a
result of this change, there is an impaired sorting of
BDNF into secretory vesicles [11]. This impairment
might lead to a reduction of proBDNF release, which
is the major BDNF isoform present in secretory vesi-
cles. Consequently, carriers of the Met allele would
express lower baseline levels of proBDNF compared
to the carriers of the Val allele. It is unknown,
however, whether reduced level of proBDNF could
affect mBDNF levels by other compensatory mecha-
nisms. Further studies are required in order to eluci-
date the relationship between BDNF polymorphism
and proBDNF expression in the CACI setting.
The strengths of this study include its prospective
nature and the longitudinal assessment of cognitive
function and behavioral symptoms. Since the
manifestation of CACI is complex and can be
influenced by multiple factors, documented
confounders [12, 18] such as anxiety, fatigue and
depression (using BAI, BFI and BDI) were also evalu-
ated in this study. However, one major limitation was
the relatively small sample size that subjects this
study to Type 2 errors. A study with larger sample
size is required to confirm this finding. This study
also lacks an objective assessment of cognitivefunction using neuropsychological batteries, as recom-
mended by the International Cognition and Cancer
Task Force [32]. A larger sample size, as well as a
replication of the findings of this study in an inde-
pendent cohort at a different site deems important.
Hence, future studies should validate the findings of
this study.
Conclusions
In this pilot study, we have observed a statistically
significant change in BDNF levels post-chemotherapy.
After adjusting for potential confounders, a change in
BDNF levels was associated with self-perceived con-
centration deficit. BDNF levels, however, remain simi-
lar over time among carriers of the Met homozygous
carriers of the BDNF rs6265 polymorphism. Given
the complexity of BDNF and cognitive function, add-
itional studies taking into account proBDNF, MMP,
and plasmin should be conducted in order to gain a
better understanding of the contribution of the vari-
ous BDNF isoforms to CACI.
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